Efficacy of low dose atorvastatin in diabetic dyslipidaemia

Journal of the Indian Medical Association

Volumn 107, Issue 11, 2009, Pages 807-809

  Pola, Pramod ^a   Kumar, Ravishankar ^a   Amaresh, Reddy P ^a   Rajagopal, G ^a   Harinarayan, C V ^a   Suresh, V ^a   Suchitra, M M ^a,b   Sachan, Alok ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Biochemistry ^*  (India)

Author keywords

Dyslipidaemia; Low dose atorvastatin; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; INDIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; AGED; BLOOD; CLINICAL TRIAL; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 77954906982     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. American Diabetes Association - Aspirin therapy in diabetes. Diabetes Care 2004; 27: S72-3.
2. Wilson PWF, Kannel WB - Epidemiology of hyperglycemia and atherosclerosis. In: Ruderman N, Williamson J, Brownlee M, editors. Hyperglycemia, Diabetes, and Vascular Disease. New York: Oxford University Press, 1992: 21-9.
3. Scandinavian Simvastatin Survival Study Group - Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al - The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
5. Ahn SC - Neuromuscular complications of statins. Phys Med Rehabil Clin North Am 2008; 19: 47-59.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults - Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
7. Heart Protection Study Collaborative Group - MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Koren MJ, Hunninghake DB - Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: ALLIANCE Investigators. J Am Coll Cardiol 2004; 44: 1772-9.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al - European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al - Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
11. ADA - Standards of Medical Care in Diabetes-2009. Diabetes Care 2009; 32: S13-61.
12. Save V, Patil N, Moulik N, Rajadhyaksha G - Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther 2006; 11: 262-70.